Research
Hormonal
Tirzepatide is associated with a higher incidence of gastrointestinal adverse events (nausea, vomiting, diarrhea) compared to placebo and basal insulin, which can lead to treatment discontinuation.
Tirzepatide often causes stomach problems like nausea, vomiting, and diarrhea, especially at higher doses (10mg and 15mg). These side effects are more common than with placebo or basal insulin and can cause some people to stop taking the medication. Starting at a lower dose and increasing slowly may help.
StrongQualifiesHIGH confidence
Nausea was more frequent with tirzepatide vs placebo, especially with tirzepatide 15 mg... Tirzepatide 15 mg led to higher discontinuation rate of study medication due to adverse events regardless of comparator
Why this rating
Meta-analysis of 7 RCTs.
Source
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Thomas Karagiannis et al. · Diabetologia · 2022
DOI 10.1007/s00125-022-05715-4
Meta-analysis · 7 studiesCited 256×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide (5, 10, and 15 mg once-weekly) provides superior glycemic control (HbA1c reduction) and greater body weight loss compared to placebo, GLP-1 receptor agonists, and basal insulin in adults with type 2 diabetes.Strong
- Tirzepatide does not increase the risk of hypoglycemia compared to placebo and has a lower risk compared to basal insulin.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →